Current opinion in hematology
-
Curr. Opin. Hematol. · Nov 2017
ReviewNovel therapeutic approaches for thrombotic thrombocytopenic purpura.
Acquired thrombotic thrombocytopenic purpura is an immune-mediated thrombotic microangiopathy caused by antibodies to ADAMTS13 (A Disintegrin And Metalloproteinase with a ThromboSpondin type 1 motif, member 13). Standard treatment with therapeutic plasma exchange and immunosuppression with steroids results in high remission and low mortality rates. However, a number of patients remain refractory to frontline therapy and/or experience multiple relapses. This study reviews emerging therapies for thrombotic thrombocytopenic purpura. ⋯ Approximately half of patients diagnosed with acquired thrombotic thrombocytopenic purpura experience refractory and/or relapsing disease. For these patients, a hematologic remission may be an insufficient therapeutic goal. With recent developments, it is now possible to envision a multifaceted approach targeting disease mechanisms that may dramatically improve outcomes for this otherwise debilitating disease.
-
Curr. Opin. Hematol. · Nov 2017
ReviewPrehospital hemostatic resuscitation to achieve zero preventable deaths after traumatic injury.
To describe how hemostatic resuscitation can be used in the prehospital phase of resuscitation to reduce preventable deaths after traumatic injury. ⋯ Prehospital hemostatic resuscitation has the potential to significantly reduce preventable death from hemorrhage.